JP2002531543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531543A5 JP2002531543A5 JP2000586684A JP2000586684A JP2002531543A5 JP 2002531543 A5 JP2002531543 A5 JP 2002531543A5 JP 2000586684 A JP2000586684 A JP 2000586684A JP 2000586684 A JP2000586684 A JP 2000586684A JP 2002531543 A5 JP2002531543 A5 JP 2002531543A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- compound according
- amino acid
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000004215 Carbon black (E152) Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- 150000002430 hydrocarbons Chemical class 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229910052717 sulfur Chemical group 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 229940009976 deoxycholate Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11178498P | 1998-12-10 | 1998-12-10 | |
| US60/111,784 | 1998-12-10 | ||
| PCT/US1999/029119 WO2000034236A1 (en) | 1998-12-10 | 1999-12-09 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002531543A JP2002531543A (ja) | 2002-09-24 |
| JP2002531543A5 true JP2002531543A5 (https=) | 2007-04-05 |
| JP4637362B2 JP4637362B2 (ja) | 2011-02-23 |
Family
ID=22340445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586684A Expired - Fee Related JP4637362B2 (ja) | 1998-12-10 | 1999-12-09 | 可逆性水性ｐＨ感受性脂質化剤、組成物および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6590071B1 (https=) |
| EP (1) | EP1137631B1 (https=) |
| JP (1) | JP4637362B2 (https=) |
| KR (1) | KR100676419B1 (https=) |
| CN (1) | CN1168711C (https=) |
| AR (1) | AR021604A1 (https=) |
| AT (1) | ATE265429T1 (https=) |
| AU (1) | AU764035B2 (https=) |
| CA (1) | CA2354142A1 (https=) |
| DE (1) | DE69916885T2 (https=) |
| EA (1) | EA200100652A1 (https=) |
| ES (1) | ES2220141T3 (https=) |
| HK (1) | HK1045681B (https=) |
| IL (2) | IL143578A0 (https=) |
| TW (1) | TWI242000B (https=) |
| WO (1) | WO2000034236A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US8541548B2 (en) * | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
| US7019113B2 (en) * | 1999-06-07 | 2006-03-28 | Mirus Bio Corporation | Reversible modification of membrane interaction |
| US7442764B2 (en) * | 1999-06-07 | 2008-10-28 | Mirns Bio Corporation | Reversible modification of amine-containing compounds |
| US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| CN100350968C (zh) | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
| EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
| US8138383B2 (en) * | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
| US8008355B2 (en) * | 2002-03-11 | 2011-08-30 | Roche Madison Inc. | Endosomolytic poly(vinyl ether) polymers |
| US20040152880A1 (en) * | 2002-11-22 | 2004-08-05 | Carnegie Mellon University | Compositions and methods for the reversible capture of biomolecules |
| US20040151766A1 (en) * | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| US20050054612A1 (en) * | 2003-09-08 | 2005-03-10 | Monahan Sean D. | Delivery by labile hydrophobic modification of drugs |
| US20090074885A1 (en) * | 2003-09-08 | 2009-03-19 | Roche Madison Inc. | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells |
| FR2880627B1 (fr) * | 2005-01-07 | 2007-05-18 | Silab Sa | Procede d'obtention d'un principe actif pour l'eclat du teint, principe actif obtenu et compositions associees |
| KR100726281B1 (ko) * | 2006-07-31 | 2007-06-11 | (주)아모레퍼시픽 | 신규 지방산 에스테르 화합물 및 이를 유효성분으로함유하는 당뇨 및 비만치료용 조성물 |
| CN101500548A (zh) * | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| WO2008057298A2 (en) * | 2006-10-27 | 2008-05-15 | Wei-Chiang Shen | Lipidized interferon and uses thereof |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| WO2009059984A2 (en) * | 2007-11-06 | 2009-05-14 | F. Hoffmann-La Roche Ag | Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2962504A (en) * | 1960-11-29 | Production of maleic anhydride | ||
| US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4480106A (en) * | 1981-10-28 | 1984-10-30 | Ciba-Geigy Corporation | Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4764368A (en) | 1984-08-29 | 1988-08-16 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4751286A (en) | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
| US4889916A (en) | 1985-11-19 | 1989-12-26 | The Johns Hopkins University | Protein label and drug delivery system |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5017693A (en) | 1987-12-02 | 1991-05-21 | Neorx Corporation | Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound |
| US5066490A (en) | 1988-06-01 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Protein crosslinking reagents cleavable within acidified intracellular vesicles |
| US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| US5907030A (en) * | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| CZ289343B6 (cs) * | 1995-03-17 | 2002-01-16 | Novo Nordisk A/S | Inzulinový derivát a farmaceutický prostředek pro léčení diabetes |
| US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5907530A (en) | 1995-08-30 | 1999-05-25 | Samsung Electronics Co., Ltd. | Optical pickup device |
| CN1127477C (zh) | 1996-09-26 | 2003-11-12 | 南加利福尼亚大学 | 用于亲水分子脂质化的方法和组合物 |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
-
1999
- 1999-12-06 TW TW088121325A patent/TWI242000B/zh active
- 1999-12-09 EA EA200100652A patent/EA200100652A1/ru unknown
- 1999-12-09 KR KR1020017007259A patent/KR100676419B1/ko not_active Expired - Fee Related
- 1999-12-09 ES ES99967238T patent/ES2220141T3/es not_active Expired - Lifetime
- 1999-12-09 HK HK02107065.3A patent/HK1045681B/zh not_active IP Right Cessation
- 1999-12-09 IL IL14357899A patent/IL143578A0/xx active IP Right Grant
- 1999-12-09 JP JP2000586684A patent/JP4637362B2/ja not_active Expired - Fee Related
- 1999-12-09 CN CNB998142441A patent/CN1168711C/zh not_active Expired - Fee Related
- 1999-12-09 US US09/457,587 patent/US6590071B1/en not_active Expired - Fee Related
- 1999-12-09 CA CA002354142A patent/CA2354142A1/en not_active Abandoned
- 1999-12-09 AU AU23556/00A patent/AU764035B2/en not_active Ceased
- 1999-12-09 WO PCT/US1999/029119 patent/WO2000034236A1/en not_active Ceased
- 1999-12-09 AR ARP990106275A patent/AR021604A1/es unknown
- 1999-12-09 DE DE69916885T patent/DE69916885T2/de not_active Expired - Lifetime
- 1999-12-09 AT AT99967238T patent/ATE265429T1/de not_active IP Right Cessation
- 1999-12-09 EP EP99967238A patent/EP1137631B1/en not_active Expired - Lifetime
-
2001
- 2001-06-05 IL IL143578A patent/IL143578A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531543A5 (https=) | ||
| JP4878732B2 (ja) | 規制物質の濫用を防ぐための新規な持続放出製薬化合物 | |
| KR101159559B1 (ko) | 신규의 인슐린 유도체 | |
| RU2676324C2 (ru) | Пролекарство, содержащее саморасщепляемый линкер | |
| US7153930B1 (en) | Peptide transport | |
| KR101186851B1 (ko) | 신규의 인슐린 유도체 | |
| BRPI0409322B1 (pt) | método para preparar um conjugado de insulina-polímero | |
| RU98104253A (ru) | Новые опиоидные пептиды | |
| EP1423136A1 (en) | Polypeptide conjugates with extended circulating half-lives | |
| EP2673004A1 (en) | Hydrophobic modified peptides and their use for liver specific targeting | |
| TWI242000B (en) | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use | |
| WO2020035027A1 (zh) | 连接子、含连接子的抗体偶联药物及连接子的用途 | |
| CN106232131A (zh) | 生长抑素和其类似物的结合物 | |
| JP2002503714A5 (https=) | ||
| Alsenz et al. | Oral absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine | |
| CN101959532B (zh) | 经鼻给药用药物组合物 | |
| JP2000191700A (ja) | 持続型消化管運動ペプチド | |
| RU2730848C2 (ru) | Способы пэгилирования по аминогруппе для получения сайт-специфичных конъюгатов белков | |
| US10167326B2 (en) | Alpha-fetoprotein “ring and tail” peptides | |
| RU2798085C2 (ru) | Пролекарство, содержащее саморасщепляемый линкер | |
| WO2025261479A1 (zh) | 以丁二酰基为连接链的偶联物及其制备方法和用途 | |
| JP2023551480A (ja) | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 | |
| JPS62263198A (ja) | 細胞保護作用を有する環状ペプチド | |
| CN1187771A (zh) | 用氧化氮释放剂治疗阳痿 |